Cargando…

Immunogenicity and reactogenicity of the human rotavirus vaccine, RIX4414 oral suspension, when co-administered with routine childhood vaccines in Chinese infants

This study evaluated the immunogenicity of the human rotavirus (RV) vaccine (RIX4414) when co-administered with routine childhood vaccines in Chinese infants (NCT01171963). Healthy infants aged 6–16 weeks received 2 doses of either RIX4414 or placebo according to a 0, 1-month schedule. Infants recei...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Rong-cheng, Huang, Teng, Li, Yanping, Wang, Lao-Hong, Tao, Junhui, Fu, Botao, Si, Guoai, Nong, Yi, Mo, Zhaojun, Liao, XueYan, Luan, Ivy, Tang, Haiwen, Rathi, Niraj, Karkada, Naveen, Han, Htay Htay
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2015
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4964624/ https://www.ncbi.nlm.nih.gov/pubmed/27149266 http://dx.doi.org/10.1080/21645515.2015.1085143

Ejemplares similares

Human rotavirus vaccine (RIX4414) efficacy in the first two years of life: A randomized, placebo-controlled trial in China
por: Li, Rong-cheng, et al.
Publicado: (2014)

Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: Randomized, double-blind, placebo-controlled Phase I studies
por: Li, Rong-Cheng, et al.
Publicado: (2013)

Post-marketing safety surveillance conducted in Korea (2008–2013) following the introduction of the rotavirus vaccine, RIX4414 (Rotarix™)
por: Shin, Son Moon, et al.
Publicado: (2016)

Early exposure of infants to natural rotavirus infection: a review of studies with human rotavirus vaccine RIX4414
por: Cunliffe, Nigel, et al.
Publicado: (2014)

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries
por: Plosker, Greg L.
Publicado: (2012)

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
por: Knoll, Stefanie, et al.
Publicado: (2013)

The human rotavirus vaccine Rotarix™ in infants: An integrated analysis of safety and reactogenicity
por: Buyse, Hubert, et al.
Publicado: (2014)

Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis
por: Rose, Johnie, et al.
Publicado: (2009)

Reactogenicity and safety of the human rotavirus vaccine, Rotarix™ in The Philippines, Sri Lanka, and India: A post-marketing surveillance study
por: Bravo, Lulu, et al.
Publicado: (2014)

Serologic response to porcine circovirus type 1 (PCV1) in infants vaccinated with the human rotavirus vaccine, Rotarix™: A retrospective laboratory analysis
por: Han, Htay Htay, et al.
Publicado: (2016)

T7 expression plasmids for producing a recombinant human G1P[8] rotavirus comprising RIX4414 sequences of the RV1 (Rotarix , GSK) vaccine strain
por: Philip, Asha A., et al.
Publicado: (2023)

Association of serum anti-rotavirus immunoglobulin A antibody seropositivity and protection against severe rotavirus gastroenteritis: Analysis of clinical trials of human rotavirus vaccine
por: Cheuvart, Brigitte, et al.
Publicado: (2014)

Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: An open-label, phase III study
por: Anh, Dang Duc, et al.
Publicado: (2015)

Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination
por: Steele, A. Duncan, et al.
Publicado: (2016)

Human rotavirus vaccine Rotarix™ provides protection against diverse circulating rotavirus strains in African infants: a randomized controlled trial
por: Steele, Andrew Duncan, et al.
Publicado: (2012)

The how’s and what’s of vaccine reactogenicity
por: Hervé, Caroline, et al.
Publicado: (2019)

Quanty4RIXS: a program for crystal field multiplet calculations of RIXS and RIXS–MCD spectra using Quanty
por: Zimmermann, Patric, et al.
Publicado: (2018)

Immunogenicity and safety of 3-dose primary vaccination with combined DTPa-HBV-IPV/Hib in Indian infants
por: Lalwani, Sanjay K., et al.
Publicado: (2016)

Methods for predicting vaccine immunogenicity and reactogenicity
por: Gonzalez-Dias, Patrícia, et al.
Publicado: (2019)

A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants
por: Kanchan, Vibhu, et al.
Publicado: (2019)

Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
por: Ambrosino, Donna, et al.
Publicado: (2021)

Mr. William Howells Rix
Publicado: (1910)

Immunogenicity and Reactogenicity in Q Fever Vaccine Development
por: Fratzke, Alycia P., et al.
Publicado: (2022)

Unorthodox branching ratios of the psi'''(4.414) as radial excitation of charmonium
por: Caichian, M, et al.
Publicado: (1978)

Prevalence of COVID‐19 vaccine reactogenicity among Bangladeshi physicians
por: Majumder, Md. Anwarul Azim, et al.
Publicado: (2022)

Rotaviruses and Rotavirus Vaccines
por: Donato, Celeste M., et al.
Publicado: (2021)

COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis
por: Briggs, Farren Basil Shaw, et al.
Publicado: (2021)

Reactogenicity to COVID-19 vaccination in the United States of America
por: Sanyaolu, Adekunle, et al.
Publicado: (2022)

Immunogenicity and Reactogenicity of Coadministration of COVID-19 and Influenza Vaccines
por: Gonen, Tal, et al.
Publicado: (2023)

Editorial: Non-reactogenic vaccines against Q-fever
por: Gregory, Anthony E., et al.
Publicado: (2023)

Immunogenicity and reactogenicity of yellow fever vaccine in people with HIV
por: Motta, Edwiges, et al.
Publicado: (2023)

4414 Collagen Dermal Replacement Scaffold Mechanobiology in Treatment of Difficult-to-Heal Wounds
por: Sohutskay, David Oleh, et al.
Publicado: (2020)

1087 Immunogenicity and Safety of 3-Dose Primary Vaccination with Combined DTPa-HBV-IPV/Hib Vaccine in Canadian Aboriginal and non-Aboriginal Infants
por: Scheifele, David W., et al.
Publicado: (2014)

Benefit Versus Risk Assessment of Rotavirus Vaccination in France: A Simulation and Modeling Analysis
por: Ledent, Edouard, et al.
Publicado: (2018)

Non-interference of Bovine-Human reassortant pentavalent rotavirus vaccine ROTASIIL® with the immunogenicity of infant vaccines in comparison with a licensed rotavirus vaccine()
por: Desai, Sajjad, et al.
Publicado: (2018)

Concomitant administration of COVD-19 vaccines with 'flu vaccines: acceptable reactogenicity profiles
Publicado: (2021)

Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants
por: Li, Yanping, et al.
Publicado: (2016)

Standardized guinea pig model for Q fever vaccine reactogenicity
por: Baeten, Laurie A., et al.
Publicado: (2018)

Can reactogenicity predict immunogenicity after COVID-19 vaccination?
por: Hwang, Young Hoon, et al.
Publicado: (2021)

Reactogenicity and Immunogenicity of the Pfizer and AstraZeneca COVID-19 Vaccines
por: Mahallawi, Waleed H., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pb7140udc7hu6a60rdpi9lsh02